Stengone Carmine N. 4

What Happened Carmine N. Stengone, CEO, President and a director of Contineum Therapeutics (CTNM), exercised stock option/derivative awards and immediately sold the resulting shares under a pre-established trading plan. On Feb 24, 2026 he exercised 4,400 shares at $1.26/share (cost $5,544) and sold those 4,400 shares for total proceeds reported as $70,486. On Feb 25, 2026 he exercised 2,700 shares at $1.26/share (cost $3,402) and sold those 2,700 shares for total proceeds reported as $43,242. Combined, 7,100 shares were sold for reported gross proceeds of $113,728; the exercise cash paid was $8,946.

Key Details

• Transaction dates: Feb 24, 2026 (4,400 shares) and Feb 25, 2026 (2,700 shares). Form filed Feb 26, 2026.
• Exercise price paid: $1.26 per share for the exercised options (total exercise cost $8,946).
• Sale price (weighted averages reported): $16.02 per share for the sold shares (proceeds $70,486 and $43,242). Footnotes state sale price ranges: 4,400-share sales at $16.00–$16.15 and 2,700-share sales at $16.00–$16.05.
• These transactions were effected pursuant to a 10b5-1 trading plan adopted Sept 23, 2025 (footnote).
• Options were fully vested and exercisable (footnote).
• Shares owned after the transactions are not specified in the Form 4 filing.
• Filing shows no indication that the report was late.

Context

• This was an exercise of vested options followed by open-market sales (commonly a cashless or immediate sale after exercise). Such transactions are routinely executed under pre-set 10b5-1 plans and are not, by themselves, a clear signal of insider sentiment.